Accessibility Menu
Star Combo Pharma logo

Star Combo Pharma(ASX) S66

Market CapA$16.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-83%
5 Year-64%
1 Year-29%
1 Month+8%
A$0.13
+0.00%
+0.00Today
Star Combo Pharma last closing stock price
MetricPriceDate
Last closeAUD 0.132026-07-31
Star Combo Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.33%AUD 0.122026-07-24
1 month+8.33%AUD 0.122026-07-01
3 month-42.22%AUD 0.232026-05-01
Year to date-50%AUD 0.262025-12-31
1 year-28.55%AUD 0.182025-07-30
3 year+15.15%AUD 0.112023-07-21
5 year-63.92%AUD 0.362021-07-30
Since inception-82.87%AUD 0.762018-05-16

Star Combo Pharma Financials at a Glance

Market Cap

A$16.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$53.53M

Net Income (TTM)

A$6.28M

EPS (TTM)

A$0.04

P/E Ratio

3.01

Dividend

A$0.00

Beta (Volatility)

-0.08 (Low)

Price

A$0.13

Volume

0

Open

A$0.13

Previous Close

A$0.13

Daily Range

A$0.13 - A$0.13

52-Week Range

A$0.10 - A$0.28

Estimated Earnings Date

Feb 24, 2026

S66 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Star Combo Pharma

Star Combo Pharma Limited is a dynamic player in the health foods and dietary supplements sector, operating primarily in Australia and China. The company specializes in the development, manufacturing, and distribution of natural health supplements and skincare products through its two main divisions: Star Combo and Austoyou Retail.

Products and Services
  • Health foods and dietary supplements tailored for health-conscious consumers
  • Skincare products developed with a focus on natural ingredients
  • E-commerce platform catering to the Chinese market alongside retail stores in Sydney
Growth Outlook
  • Expansion into the Chinese market is expected to drive significant revenue growth
  • Recent quarterly revenue reached AUD 11.93 million, indicating strong demand
  • Investment in e-commerce is anticipated to enhance market reach and customer engagement
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 47.5 million reflects a solid performance
  • Net income margin of 22.59% demonstrates effective cost management
  • Current ratio of 6.64 indicates strong liquidity and financial health
Star Combo Pharma Limited has established itself as a key player in the health and wellness industry, leveraging its expertise in natural products to meet growing consumer demand. The company's strategic focus on e-commerce and international expansion positions it well for future growth. Recent financial performance highlights, including a robust revenue stream and healthy profit margins, underscore the company's operational efficiency and market potential. With a commitment to quality and innovation, Star Combo Pharma Limited is poised to capitalize on emerging trends in the health and wellness sector.
AI Generated • Jul 22, 2026

Industry

Personal Products

CEO

Su Zhang, MBA

Headquarters

Smithfield, NSW 2164, AU

S66 Financials

Key Financial Metrics (TTM)

Gross Margin

22.73%

Operating Margin

-1.71%

Net Income Margin

22.59%

Return on Equity

14.06%

Return on Capital

-0.57%

Return on Assets

11.46%

Earnings Yield

33.22%

Dividend Yield

3.08%

Payout Ratio

9.28%

Stock Overview

Market Cap

A$16.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

135.00M

Volume

0

Avg. Volume

25.88K

Financials (TTM)

Gross Profit

A$11.66M

Operating Income

A$534.37K

EBITDA

A$8.27M

Operating Cash Flow

A$11.69M

Capital Expenditure

-A$1.51M

Free Cash Flow

A$10.19M

Cash & ST Invst.

A$18.18M

Total Debt

A$8.29M

Star Combo Pharma Performance Analysis

Star Combo Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 22,880,414N/A
20232023-06-30AUD 24,700,2778.0%
20242024-06-30AUD 26,019,1015.3%
20252025-06-30AUD 27,811,5486.9%
Star Combo Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3012.7%
Q22024-12-3015.4%
Q42025-06-30-25.2%
Q22025-12-310.2%
Star Combo Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.01N/A
20232023-06-30AUD -0.03469.2%
20242024-06-30AUD 0.01N/A
20252025-06-30AUD 0.04607.3%
Star Combo Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30360.0%
Q22024-12-30-56.5%
Q42025-06-301300.0%
Q22025-12-31-88.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$11.93M

-2.5%

Gross Profit

A$2.53M

-1.9%

Gross Margin

21.18%

N/A

Market Cap

A$16.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$540.01K

N/A

Employees

30

N/A

Net Income

A$413.24K

+228.7%

EBITDA

A$553.04K

+40.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$18.18M

+97.8%

Total Debt

A$8.29M

+101.6%

Accounts Receivable

A$2.42M

-26.1%

Inventory

A$3.73M

-6.0%

Long Term Debt

A$8.00M

+102.3%

Short Term Debt

A$290.18K

-1.3%

Return on Assets

11.46%

N/A

Return on Invested Capital

-0.94%

N/A

Free Cash Flow

A$279.70K

+337.6%

Operating Cash Flow

A$575.23K

+13.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NUC.AXNuchev Limited
A$0.09+0.00%
AHF.AXAustralian Dairy Nutritionals Limited
A$0.02+6.25%
ZNO.AXZoono Group Limited
A$0.05+0.00%
MCP.AXMcPherson's Limited
A$0.15-3.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About S66

What is the current price of Star Combo Pharma?

Star Combo Pharma is trading at A$0.13 per share.

What is the 52-week range for Star Combo Pharma?

Over the past 52 weeks, Star Combo Pharma has traded between A$0.10 and A$0.28.

How much debt does Star Combo Pharma have?

As of the most recent reporting period, Star Combo Pharma reported total debt of A$3.93M.

How much cash does Star Combo Pharma have on hand?

Star Combo Pharma reported A$3.59M in cash and cash equivalents in its most recent financial results.

What is Star Combo Pharma’s dividend yield?

Star Combo Pharma currently has a dividend yield of 3.08%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.